Dem Bundesamt für Sicherheit im Gesundheitswesen (BASG) wurde von der ECDC (European Centre for Disease Prevention and Control) mitgeteilt, dass in Nord-Mazedonien, in Vadar humane WNV-Infektionen verzeichnet wurden. Um entsprechende Beachtung in den Anamnesegesprächen und Spenderselektionen wird daher gebeten. Dieses Schreiben entspricht dem aktuellen Informationsstand des BASG. Sobald weitere Informationen vorliegen, werden diese bekannt gegeben.

Referenced at:

• West Nile Virus (WNV) - North Macedonia

The Federal Office for Safety in Health Care (BASG) has been informed by the ECDC (European Centre for Disease Prevention and Control) that human WNV infections have been recorded in North Macedonia, in Vardar.

Precautionary batch recall, as there may be glass splinters in the bottles

Recall due to possible contamination with glass splinters

Recall due to reduced release of active pharmaceutical ingredient

FAQ National stockpiling 1. What reporting obligations do marketing authorisation holders have under the Ordinance on Stockpiling of Medicinal Products for Human Use? 2. Who can submit a stockpiling d

Many of the offered "peptides" are classified as medicinal products without marketing authorisation by the Austrian Federal Office for Safety in Health Care (BASG) depending on their composition, concentration, effects and scientific data.

The BASG warns against illegal medicinal products (illegal medicinal product by presentation) marketed under the misleading name "GLP-1" because of their claims.

The Federal Office for Safety in Health Care (BASG) warns of a counterfeit medical device that could be mistaken for the legitimate product "Juvéderm Ultra 4" from the manufacturer "Allergan Aesthetics, an AbbVie company".

The Federal Office for Safety in Health Care (BASG) warns against the use of rapid tests for the detection of sexually transmitted diseases (STDs) that were distributed via the website „thuistest.shop“ and “stdheimtest.de“. Based on the information available to the BASG, the legal compliance of the affected products cannot be sufficiently demonstrated and therefore the safety and performance of the products cannot be ensured. For this reason, the listed products are not allowed to be placed on the Union Market.